Canada Pension Plan Investment Board Buys Shares of 115,805 BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Canada Pension Plan Investment Board acquired 115,805 BioCryst Pharmaceuticals shares valued at approximately $1.16 million during the second quarter. Institutional investors now own 85.88% of the company.
• Analysts maintain a generally positive outlook, with eight Buy ratings and four Hold ratings producing a consensus “Moderate Buy” rating and average price target of $20.60.
• BioCryst reported quarterly earnings of $0.30 per share, beating estimates of $0.15, while revenue rose 33.6% year over year to $218.25 million. Shares opened at $9.70, near their 50-day moving average.

Canada Pension Plan Investment Board bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 115,805 shares of the biotechnology company's stock, valued at approximately $1,158,000.

A number of other large investors have also recently made changes to their positions in BCRX. Parkman Healthcare Partners LLC purchased a new position in shares of BioCryst Pharmaceuticals in the second quarter valued at $16,243,000. Legal & General Group Plc purchased a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth about $14,555,000. The Manufacturers Life Insurance Company purchased a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth about $1,195,000. Visionary Wealth Advisors bought a new position in BioCryst Pharmaceuticals in the 2nd quarter worth about $169,000. Finally, Sanctuary Advisors LLC bought a new position in BioCryst Pharmaceuticals in the 2nd quarter worth about $587,000. 85.88% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on BCRX. Royal Bank Of Canada reduced their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating for the company in a report on Thursday, August 6th. Citizens Jmp increased their price target on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a "market outperform" rating in a report on Thursday, May 7th. JPMorgan Chase & Co. assumed coverage on shares of BioCryst Pharmaceuticals in a research report on Monday, July 13th. They issued a "neutral" rating and a $12.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $32.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Finally, Wedbush decreased their target price on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $20.60.

BioCryst Pharmaceuticals Trading Down 1.2%

Shares of NASDAQ BCRX opened at $9.70 on Tuesday. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $11.22. The firm has a market capitalization of $2.48 billion, a price-to-earnings ratio of -6.47 and a beta of 0.55. The business has a 50-day moving average of $9.73 and a 200-day moving average of $9.09.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.15. The company had revenue of $218.25 million for the quarter, compared to analysts' expectations of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. BioCryst Pharmaceuticals's revenue for the quarter was up 33.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.15 earnings per share. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.